The market opened in the green on February 14, 2020, overall volumes in futures & options currently stand at 4.15 crore contracts with a turnover of Rs. 28,46,771.71 crore.

The market opened in the green on February 14, 2020. The previous trading session witnessed the Sensex going down by 106.11 points to end at 41,459.79 and the Nifty was down by 26.55 points to close at 12,174.65.

The market opened in the green on February 14, 2020. The previous trading session witnessed the Sensex going down by 106.11 points to end at 41,459.79 and the Nifty was down by 26.55 points to close at 12,174.65. 

There can be innumerable reasons for you to sell stocks. However, read on to find the tax and non-tax issues that should prompt you to sell your investments:

Real estate has been one of the most preferred asset classes since the time of our ancestors. However, there are a few things that one needs to consider before investing in real estate.

Wednesday’s high of 12,232 will act as a crucial resistance for the time being. Any close below 50-DMA, 12,126 will be a bearish sign. Watch the zone of 12,126-12,232 for a trending confirmation.

The rally, which began in the last leg of trade yesterday, where Nifty recouped 35 points from lower levels, is likely to continue this morning as indicated by SGX Nifty, which is trading in green with gains of 35 points at 12,186. The first task for the bulls would be to move above 12,200 mark and if Nifty holds above 12,200 mark, we believe that it will try to test 12,272 mark.

While investing with a global perspective in mind, one has to realise that the largest market cap firm in one’s own country, may be a small-cap company in the global perspective.

The following stocks will be in focus during Friday’s trading session in the light of their result announcements-Balkrishna Industries, Edelweiss Financial Services, Finolex Cables, Gabriel India and ARSS Infrastructure Projects.

Granules India informed the bourses on Thursday that the company received tentative approval for its Abbreviated New Drug Application (ANDA) from US Food and Drug Administration (USFDA) for Guaifenesin Extended-release tablets, 600 mg and 1,200 mg.